Early Tumor Screening
It is a technology for the new detection
Scenarios with very urgent needs
Early detection, early diagnosis and early treatment
Can greatly improve the prognosis of the patient's survival time in the gene sequencing laboratory on the 2nd floor of the headquarters of Shiho Genetics in Nanjing's Jiangbei New District, the fully automated sequencers are running 24 hours a day. "These sequencers are just auxiliary, imported products, but the core technology of detection is our own research and development." Detectors said.The product adopts more than 20,000 probes independently designed by Shihe, each probe is individually synthesized, quality controlled and repeatedly optimized for 14 rounds, covering a high degree of uniformity.The
"When a tumor begins to develop, the body's genome develops features that are different from those of a healthy person. By capturing and identifying these features, we can detect abnormal tumor signals. However, the challenge is how to accurately identify tumor signals on the genome while eliminating interfering factors." said Zhao Yvette Chao, co-founder of Nanjing Shihe Gene Biotechnology Co.
To this end, Seiwa Genetics has developedEagle Eye CanScan ProductsThe MERCURY multi-omics liquid biopsy technology was developed in-house.
put it simply
Just "one tube of blood."
It's a one-time screening.
9 Highly Prevalent Cancers
Including lung, liver, and intestinal cancers
Once abnormal signals are detected, Eagle Eye CanScan can also locate the specific site of the signal source. This technology has been clinically validated in pan-cancer as well as single cancer types, and the related research results have been published in international authoritative journals.The sensitivity and specificity of Hawkeye CanScan for stage I tumors have reached the world's advanced level.The
furthermore
A product called "Shiho No. 1".
Genetic testing kits
at first glance it looks ordinary
the fact is ...The first approved domestic
NGS (Next Generation Sequencing)
Big Panel Oncology Genetic Testing Products
alsoFirst tumor immunotherapy
New marker products for efficacy prediction
Coverage is related to tumor development and
425 key genes highly associated with treatment prognosis
The product was approved for listing in October last year, which is the only innovative in vitro diagnostic product listed in our province last year, and also the only innovative medical device in vitro diagnostic product listed in China last year.
The efficacy of many anticancer drugs is closely related to the genotyping of patients, and only by relying on genetic testing to find cancer biomarkers can we truly realize "prescribing the right medicine and striking the right blow" in medicine. With the extensive use of targeted therapy and immunotherapy in the clinic, the market for tumor genetic testing has gradually matured.
Founded in 2013, through adherence to independent innovation, the company now has nearly 60 domestic and international invention patents, and a number of core technologies and products are the first of their kind in China.
At present, the core technology and products of Shiho Genetics have obtained a number of domestic and international market access passes, and signed hundreds of millions of dollars of orders with international famous pharmaceutical companies, and reached technology export cooperation with a number of large overseas medical institutions, and participated in a number of international clinical trials. The global registration program of "Shihe No.1" Large Panel Reagent Kit is also progressing steadily, and the clinical trial in the U.S. is nearing the end, and it is expected to be declared on the market by the FDA within the year.
In order to support the innovative development of biopharmaceutical industry, Jiangsu Province issued the implementation plan of innovative drug and equipment incentive policy, "Shiho No. 1" large Panel kit won the provincial financial 6.6 million yuan free of application that is to enjoy the incentives, but also included in the provincial key to promote the application of new technologies and new product catalogs.
